<SEC-DOCUMENT>0001213900-20-037541.txt : 20201117
<SEC-HEADER>0001213900-20-037541.hdr.sgml : 20201117
<ACCEPTANCE-DATETIME>20201117081844
ACCESSION NUMBER:		0001213900-20-037541
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201117
FILED AS OF DATE:		20201117
DATE AS OF CHANGE:		20201117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		201319292

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea129902-6k_enlivextherap.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of: November 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>ENLIVEX THERAPEUTICS LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel
7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 15, 2020,
the Board of Directors (the &ldquo;<U>Board</U>&rdquo;) of Enlivex Therapeutics Ltd., a company organized under the laws of the
State of Israel (the &ldquo;<U>Company</U>&rdquo;), appointed Dr. Brian Schwartz, M.D. to serve as a Director for a term expiring
at the Company&rsquo;s 2021 Annual Meeting of Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Schwartz will participate
in the standard non-employee director compensation arrangements described in the Company&rsquo;s 2020 Proxy Statement furnished
as Exhibit 99.1 to the Company&rsquo;s Report on Form 6-K filed with the Securities and Exchange Commission on May 19, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no arrangements
or understandings between Dr. Schwartz, on the one hand, and any other person, on the other hand, pursuant to which he was appointed
to the Board. Since the beginning of the Company&rsquo;s last fiscal year, the Company has not engaged in any transactions, and
there are no proposed transactions, or series of similar transactions, in which Dr. Schwartz was or is to be a participant and
in which any related person had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
his appointment to the Board, Dr. Schwarz will receive ten-year options to purchase an aggregate of 40,500 of the Company&rsquo;s
ordinary shares, at a price of $9.02 per share, vesting ratably over a period of four years, commencing on the first anniversary
of the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 17, 2020,
the Company issued a press release announcing Dr. Schwartz&rsquo;s appointment to the Board. A copy of such press release is furnished
as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%"><A HREF="ea129902ex99-1_enlivex.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Enlivex Therapeutics Ltd. on November 17, 2020.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex Therapeutics Ltd.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Hershkovitz</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: November 17, 2020</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea129902ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON NOVEMBER 16, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">Enlivex
Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to <BR>
the Company&rsquo;s Board of Directors</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>*
<I>Dr. Schwartz Served as ArQule&rsquo;s Chief Medical Officer and Head of Research and<BR>
Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 </I>*</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nes
Ziona, Israel, November 17, 2020 (GLOBE NEWSWIRE) --&nbsp;</B>Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;),
a clinical-stage immunotherapy company, today announced that Brian Schwartz, MD, who served for twelve years as Chief Medical
Officer of ArQule, Inc. and led ArQule&rsquo;s research and development programs through its $2.7 billion acquisition by Merck
earlier this year, joined the Enlivex Board of Directors on November, 15, 2020.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Schwartz commented, &ldquo;I am excited to be joining the Board of Directors of Enlivex. After carefully reviewing the scientific
basis and data for Allocetra<SUP>TM</SUP>, which is currently in clinical development for sepsis and COVID-19, and in preclinical
development for solid cancers, I believe that this innovative immunotherapy approach has the potential to significantly impact
life-threatening, high-mortality diseases. Additionally, I believe that the planned and ongoing clinical program, coupled with
a management team that has a track-record of creating shareholder value, leaves the Company well positioned for sustained near-
and long-term growth.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Schwartz brings significant experience in drug development in both the biotechnology and pharmaceutical industries. Dr. Schwartz
most recently served as Chief Medical Officer and head of Research and Development of ArQule, Inc. where he served as a key member
of the management team and spearheaded a number of preclinical and clinical drug development programs in oncology and rare diseases.
Prior to joining ArQule in 2008, Dr. Schwartz served as Chief Medical Officer and Senior Vice President, Clinical and Regulatory
Affairs, at Ziopharm Oncology, Inc., where he built and led clinical, regulatory, and quality assurance departments responsible
for the development of new cancer drugs. Earlier in his career, Dr. Schwartz held a number of positions at Bayer Healthcare and
Leo Laboratories. At Bayer, Dr. Schwartz was a key physician responsible for the global clinical development of sorafenib (Nexavar&reg;)
and has extensive regulatory experience working with the FDA&rsquo;s Oncology Division, the European Medicines Evaluation Agency
(EMEA), and numerous other health authorities. Dr. Schwartz received his medical degree from the University of Pretoria, South
Africa, practiced medicine, and worked at the University of Toronto prior to his career in the biopharmaceutical industry. Dr
Schwartz&nbsp;is currently serves as a board member of&nbsp;Mereo Biopharma and LifeSci Acquisition Corp.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shai
Novik, Executive Chairman of the Board of Enlivex, stated, &ldquo;We are excited to have Dr. Schwartz on our Board. He has significant
relevant experience in all aspects of the product development lifecycle and shareholder value creation. We look forward to working
together.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
ENLIVEX</B><BR>
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune
system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression
of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs) such as sepsis and
COVID-19, as well as enhancement of immune activity against solid tumors in combination with CAR-T or immune checkpoint therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, visit&nbsp;http://www.enlivex.com.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Safe
Harbor Statement:&nbsp; This press release contains forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;projects,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
&ldquo;should,&rdquo; &ldquo;would&rdquo;, &ldquo;could,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo;
&ldquo;has the potential to&rdquo; and other words of similar meaning, including statements regarding expected cash balances,
market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market
opportunities for, ALLOCETRA<SUP>TM</SUP>&nbsp;programs. All such forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.&nbsp; Investors are cautioned that forward-looking statements
involve risks and uncertainties that may affect Enlivex&rsquo;s business and prospects, including the risks that Enlivex may not
succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve
the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products
for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity;
and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements.
The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other
trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage
trials. The development of any products using the ALLOCETRA<SUP>TM</SUP>&nbsp;product line could also be affected by a number
of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses
and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the
impact of patents and other proprietary rights held by competitors and other third parties.&nbsp; In addition to the risk factors
described above, investors should consider the economic, competitive, governmental, technological and other factors discussed
in Enlivex&rsquo;s filings with the Securities and Exchange Commission, including in the Company&rsquo;s most recent Annual Report
on Form 20-F filed with the Securities and Exchange Commission.&nbsp; The forward-looking statements contained in this press release
speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements,
except as required under applicable law.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENLIVEX
CONTACT</B><BR>
Shachar Shlosberger, CFO<BR>
Enlivex Therapeutics, Ltd.<BR>
shachar@enlivexpharm.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR
RELATIONS CONTACT</B><BR>
Eric Ribner<BR>
LifeSci Advisors<BR>
eric@lifesciadvisors.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "[ 2P# 2(  A$! Q$!_\0
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MCU:&0_DK&N2U3_@HA^SKI*DR_%'2YL=K6&XG/_CD9I70^678^C**^/\ 4O\
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M))SH4E%OLCIAE]*#O'0_<_5/^"JW[.VF@^7XHU'4&'\-KH]R<_BRJ*Y/4O\
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MAX=T]I8E;%QJ$V4MK8>KOCK_ +(R3Z5]]^$O"W@K]CGX4W=Y?WOF.Y$EY>N
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MEHZV;L6*A5E(VD[@1P>H-<Q0%T]@HHHH&%%%% !1110 4444 %%%% !1110
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M_P#;7WKDO^"4GCRVTOX^:UX"U1P=&\=:)<:=)$S85IHU+KQW)C\Y?^!5O?\
M!536=,\%ZI\+/@GX>;;HO@C0DD>/OYD@$:;O]KRXMW_;4T^ES"S]I[/I>Y\%
M-]VOV,_;J_;:\?\ [*<WPSTSP;::)<V^L:(;FX.JVTDK!D\M1M*R+@8)]:_'
M1ONU^A?_  6#95\0?!C) _XIR7_T.*D:UDI3BF<U_P /B/CE_P! OP=_X+I_
M_C]?)'Q<^)^K_&CXD:]XWUZ.UAUC6IQ<7,=DA2%6"*@VJ22!A1U)KCO.3^^O
MYTJR*W1@?I0;1IPB[Q1V/PA^&.J_&?XG>&_!&B+G4=;O$M5?&1$AYDE/LB!F
M/^[7["_&3X?_  \^.GPA\:_LO>#9V'BKX<:/87FG1LV0)TC)C4'/S$C"29Z&
MX'?I\K_\$]_#.F_L\_ _XB?M/>++17%E:R:9X;@FP#.^0KE,]WEV1 CH%DKY
MA^ /[3WB#X4_M-:?\6-3O)K^YO-0DDU[YCFZM[AO](7\ =RCL47TI['-43JR
M;C]G\SQ2>"6UGE@GB>">)S')%("&1@<%2#T(((IE?8__  4Z^!-K\.OC1;>/
MO#B1R^"_B!#_ &K:W%L/W(NB TP!'&'#+*/7S&]*^.*1U0DIQ4D%%%%!H%%%
M% !1110 4444 %%%% !1110 4444 %%%% ",NY2.F17Z"V__  5PNVT/1]-U
M+X,>'-9&F6D=K%-?7IE.%15)&Z$XSM!P*_/NK6HZ7>:1.D-]:S6<SQI,L<Z%
M6:-U#(P![$$$'N#09RIQG\1]\?\ #V2V_P"B >#O^_P_^,5Y)^TY^W-#^TA\
M.H/"L?PM\/\ @QHM0BO_ .T=+D#2G8KKY?\ JUX._)Y_A%?+%%!"HP3ND>\^
M"/VL;_P5^ROXR^"47ANVN['Q)>&\DUA[IEE@),)VB/;AO]0.X^\?2O!J**#5
M14=NI[+^S/\ M0>(OV9-;\176D6L>K:9K^F2:;J&EW$K1QR9!$<H(!PZ$MCC
MD,P[YKS[X8^-)/AG\1/"WBR&T34)="U*WU)+61RBS&*0.$+#) .,9KFZ* Y5
MJ^Y^ANJ?\%>I-;O&N]1^!GA:_NF !GNKOS9"!T!9H2>*JC_@K);?]$ \'?\
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>"-?1=Q.!]*J444""BBB@84444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
